LTGO-33

The sodium channel blocker market is expanding rapidly due to increasing prevalence of neuropathic pain and rising demand for selective treatments targeting Nav1.7 and Nav1.8 inhibitors.

Latigo Biotherapeutics has raised $150 million in Series B funding led by Blue Owl Capital to advance its pipeline of non-opioid pain medications targeting NaV1.8 and other pain pathways.

Latigo Biotherapeutics' LTG-001, an oral Nav1.8 inhibitor targeting acute pain, receives FDA Fast Track Designation following successful Phase 1 trial results.

Latigo Biotherapeutics has dosed the first participant in a Phase 1 clinical trial of LTG-305, a non-opioid therapeutic candidate for chronic pain treatment.

Vertex Pharmaceuticals' VX-548 (suzetrigine) demonstrates significant pain reduction in Phase 3 trials, advancing toward FDA approval as the first new acute pain medicine class in over 20 years.